knowledge -WSS

knowledge

author：Wikipedia 2025-09-28 18:39:59 - browse：193

President Joe Biden talks in the Roosevelt Room of the White House, in front of a painting of Theodore Roosevelt on a horse back — politics coverage from STAT — President Biden MANDEL NGAN/AFP via Getty Images

WASHINGTON — The White House is throwing its support behind a controversial authority that allows the government to undermine patent rights for certain high-priced medicines. It’s an early step that could have major ramifications for the American pharmaceutical industry, depending on whether and how federal officials actually use the authority.

The administration issued a framework for the National Institutes of Health to more broadly use so-called “march-in rights” — a policy that allows it to invalidate patent rights from drugmakers whose products rely on federally funded research. The framework lays out when the agency might assert this authority, and endorse using a drug’s price in that determination.

“We’ll make clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard told reporters. “These authorities are in existing laws, the last administration just didn’t want to allow them to be used in this way.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Publishing genetic code of viruses could cause disaster

leisure time

WSS

Experimental asthma app from Apple and Anthem shows promise

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Apple Vision Pro: A first look at health apps on the new VR headset

Healthy food access boosts outcomes in two studies

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

explore

knowledge

knowledge

In Memoriam: Notable people who died in 2023

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Activists slam private health insurers over coverage restrictions

Apple Vision Pro: A first look at health apps on the new VR headset

Medicare proposal to cover medical devices draws a mixed reaction

Type 2 diabetes prevention programs work at large scale: study

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Wildfire smoke exposes gaps in outdoor worker protections

General Catalyst, Summa Health deal will turn on physician buy

focus

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Ohio still needs to do more to protect the right to abortion

NIH chief: government has fallen behind pharma on clinical trials

A $475,000 price tag for a new cancer drug: crazy or meh?

FDA drug safety: Singulair case shows systemic surveillance flaws

How state and local governments are sidelining science

hotspot

leisure time

hotspot

entertainment